That the overall market sentiment towards biotechs and the WF downgrade are responsible for the PPS action today. And yes, report / news could be a significant catalyst but looking back at how the stock has reacted published good news in the past doesn't give me too much hope at this point. I am getting killed on some small positions in ziop calls. I have no one but myself to blame this is the price you pay when you over speculate. Things will get better at some point.
I did this, sold 75% of my cocp position and bought opk calls (15 sept) thinking about moving the rest over in a few minutes. I still like cocp but it is so cheap that there will be time to get back in when news starts to move share price. That may be in Sept when they file IND apps with FDA. I have a hunch that short term the Aug 10 earnings call will be our best catalyst, after that Ropilant approval, cocp IND's, Rayladee, and so forth and so on.
CAT is not in a good position going into its earnings conference next week. Steve Weiss, a good level headed trader, indicating that all of CAT's key markets are impaired and the construction spending in the most important countries, like China, has come to an almost complete stop. Current revenues and forward estimates will likely suffer greatly. If you are really wedded to this stock you should consider buying some puts going into next week.
I certainly agree with your point about saving the "poor soles" in the third world. It is usually hot in those countries and they should probably consider wearing sandals anyway.
Thank you so very much Ice for this piece of research. Meeting with my nephrologist on Thursday and taking the info into them. Will keep you guys posted and thanks so much for the help and positive thoughts.
Yes, half life is how long the drug remains in the body at a therapeutic dosage and is key not only to a drugs efficacy but also its safety. There's no question that this new formulation is a vast improvement over the current one, particularly as it relates to pediatrics because it must be given by injection so for junior it's either seven shots a week or one a week. How do you think an eight year old will come down on that question?
Yes this is an important factor as I know from personal experience. As I have mentioned before on the MB I have CKD stage three that is complicated by some stomach disorders that prevent full absorption and retention of drugs and vitamins. This exacerbates the vit D issues associated with CKD and in my case resulted in having to take a daily dose of D that would cause extreme toxicity in a normal metabolism. (50k units per day whereas most take 50K once a month, once a week sometimes but rarely for more than a 4 week period).
Because of this I have developed this enzyme in my blood that occurs after sustained high levels of vit D therapy. The enzyme essentially attempts to down regulate levels of D in the body by blocking its absorption.
My latest blood work show that my intact PTH levels are quickly climbing which means that calcification is also taking place.
So here is my idea and request that I would like to bounce off the other sincere members of this board. I am frustrated by the apparent FDA time frame that will prevent my ability to obtain Rayaldee before next year ( as it appears to me based on production and distribution considerations). One thing I can do, and each of you who might find it in your heart can do as well, is to write your US Senators and Congressman and ask that they request the FDA to see if they can expedite approval under whatever compassionate protocol is appropriate to get this drug to people who need it sooner than the standard channels.
Remember it is a modified vitamin formulation for heaven's sake! There have been no safety issues in the exhaustive set of trials already conducted by OPK. It's probably a long shot but it's something I can at least try.I really appreciate any assistance those of you here (that are not psychotic) might be able to offer. You can go on the congressional websites and leave a message there. Say you have a friend that really needs this new drug asap. Thanks all. SemiH
"don't understand" is the understatement of the century. The excitement is very justified if not a little overblown. This entire sector of biotech will be re-evaluated based on the valuation represented by the Celgene/Juno deal. This is good news indeed.
As for the where the money is going to in a deal between Celgene and Juno....um, let's just let that go for now.
You should seek a sense of humor transplant as your current one appears to be non-operative. The prior post topic was "I seen a bottom" hence the mangled grammar. Also, there are at least two other obvious malapropos that your keen syntax insight apparently failed to detect. Just pointin' out...lol.
I think the person that responds to a robo-post is the party that should stay clear not only of options but equities as well. Talking to computers is not a good sign for your financial future.
The CEO speaking at the Jefferies conference this morning said the "we will be having some conversations with the regulators before commencing the Ph. II trials" This may be the subject.
Look at what AGIO did after Cramer touted it. Went from around 35 to 130 over the following two or three weeks.
I not do think you are right. The "run" is far from over IMO. It's just starting. But entitled are you to like what you do.
Irrepective of the corrected PUMA data on Neratinib that will be "explained" on Monday night to a packed hotel ballroom of analysts and investors, it fails to overcome two significant advantages of ONT-380.
1) Unlike Neratinib ONT-380 did NOT cause dangerous grade 3 diarrhea in trial patients. A huge advantage in and of itself that would most certainly drive providers towards using the ONTY drug over Puma's Neratinib.
2) ONT-380 has been demonstrated to cross the blood brain barrier with efficacy in CNS metastasis associated with 50% of HER positive breast cancer progression. Puma's Neratinib does not.
Two extremely important distinctions that will drive research and investment interest over and above Neratinib going forward from here.
It is a new day in this particular oncology space and investors should be mindful. If you have a long position in PBYI you might consider adjusting it by buying some protective puts or, if you don't have the stomach for what looks like it is going to be wild ride come Monday, perhaps you should punt Puma altogether.
Here's to luck and here's to struggle, bring on the opening bell.